This hypothesis is supported by a study by Hao et al. (2018) which reported the potential of A-FABP as a novel functional biomarker for protumor TAM (tumor-associated macrophage) and its potential as an immunotherapy target for patients. Here, FABP4 is linked to neoplasm.